Predict your next investment

Pfizer company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
pfizer.com

See what CB Insights has to offer

Investments

42

Portfolio Exits

21

Funds

1

Partners & Customers

10

Service Providers

2

About Pfizer

Pfizer (NYSE: PFE) offers a diversified global health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge feared diseases. The company also collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Pfizer Headquarter Location

235 East 42nd Street

New York, New York, 10017,

United States

212-733-2323

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pfizer

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Pfizer in 5 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

C

Conference Exhibitors

5,302 items

D

Diabetes

1,750 items

M

Medical Devices

3,795 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

B

Biopharma Tech

260 items

Pfizer Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pfizer Rank

Latest Pfizer News

Pfizer says COVID shot 80 percent effective in young kids

May 24, 2022

China News, Data, Media Intelligence and Insights Search for: Source: News Snapshot: LOS ANGELES, May 23 (Xinhua) -- Pfizer and its German partner BioNTech said Monday that preliminary clinical data showed their three-dose COVID-19 vaccine regimen was 80 percent effective for children 6 months to 5 years old at preventing illness during the Omicron wave. The vaccine was found to elicit a strong immune response following a third dose, and was well tolerated by the kids with a majority of the side effects mild to moderate, according to the companies. The safety data for the Pfizer vaccine is based on 1,678 children under age 5 who received a third shot at least...

Pfizer Investments

42 Investments

Pfizer has made 42 investments. Their latest investment was in Zentalis Pharmaceuticals as part of their Corporate Minority - P2P on April 4, 2022.

CBI Logo

Pfizer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/27/2022

Corporate Minority - P2P

Zentalis Pharmaceuticals

$25M

Yes

1

4/26/2022

Grant - II

Resistell

Yes

1

12/1/2021

Biz Plan Competition

Medorion

Yes

3

11/18/2021

PIPE - II

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2021

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/27/2022

4/26/2022

12/1/2021

11/18/2021

11/9/2021

Round

Corporate Minority - P2P

Grant - II

Biz Plan Competition

PIPE - II

Corporate Minority - P2P

Company

Zentalis Pharmaceuticals

Resistell

Medorion

Subscribe to see more

Subscribe to see more

Amount

$25M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

3

10

10

Pfizer Portfolio Exits

21 Portfolio Exits

Pfizer has 21 portfolio exits. Their latest portfolio exit was LianBio on November 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/1/2021

IPO

18

10/28/2020

Reverse Merger

$99M

2

1/13/2020

Divestiture

$99M

1

10/10/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/13/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/1/2021

10/28/2020

1/13/2020

10/10/2019

9/13/2019

Exit

IPO

Reverse Merger

Divestiture

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

18

2

1

10

10

Pfizer Acquisitions

45 Acquisitions

Pfizer acquired 45 companies. Their latest acquisition was Biohaven Pharmaceutical on May 10, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/10/2022

Series A

$99M

$80M

Acq - Pending

6

4/11/2022

$99M

Acq - Pending

3

4/7/2022

Series C

$99M

$120M

Acquired

9

12/13/2021

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

11/17/2021

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

5/10/2022

4/11/2022

4/7/2022

12/13/2021

11/17/2021

Investment Stage

Series A

Series C

Other Venture Capital

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$80M

$120M

$99M

$99M

Note

Acq - Pending

Acq - Pending

Acquired

Subscribe to see more

Subscribe to see more

Sources

6

3

9

10

10

Pfizer Fund History

1 Fund History

Pfizer has 1 fund, including Pfizer Breakthrough Growth Initiative.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/3/2020

Pfizer Breakthrough Growth Initiative

$500M

2

Closing Date

6/3/2020

Fund

Pfizer Breakthrough Growth Initiative

Fund Type

Status

Amount

$500M

Sources

2

Pfizer Partners & Customers

10 Partners and customers

Pfizer has 10 strategic partners and customers. Pfizer recently partnered with European Commission on May 5, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

5/2/2022

Client

Belgium

Poland has no 'rationale to invoke force majeure in Pfizer vaccine deal -EU official

In April Poland 's health minister Adam Niedzielski saidWarsaw had informed the European Commission and Pfizer that itwould no longer take or pay for COVID-19 vaccines under a supplycontract co-negotiated by the EU , acknowledging this wouldtrigger a legal conflict .

1

4/27/2022

Licensor

United States

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine.

Earlier this year , Pfizer and Biohaven Pharmaceutical Holding Company Ltd. entered into an agreement for the commercialization of VYDURA .

1

4/27/2022

Partner

United States

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine.

Earlier this year , Pfizer and Biohaven Pharmaceutical Ireland DAC entered into an agreement for the commercialization of VYDURA .

1

4/26/2022

Licensor

France

Subscribe to see more

Subscribe to see more

10

4/26/2022

Licensor

France

Subscribe to see more

Subscribe to see more

10

Date

5/2/2022

4/27/2022

4/27/2022

4/26/2022

4/26/2022

Type

Client

Licensor

Partner

Licensor

Licensor

Business Partner

Country

Belgium

United States

United States

France

France

News Snippet

Poland has no 'rationale to invoke force majeure in Pfizer vaccine deal -EU official

In April Poland 's health minister Adam Niedzielski saidWarsaw had informed the European Commission and Pfizer that itwould no longer take or pay for COVID-19 vaccines under a supplycontract co-negotiated by the EU , acknowledging this wouldtrigger a legal conflict .

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine.

Earlier this year , Pfizer and Biohaven Pharmaceutical Holding Company Ltd. entered into an agreement for the commercialization of VYDURA .

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine.

Earlier this year , Pfizer and Biohaven Pharmaceutical Ireland DAC entered into an agreement for the commercialization of VYDURA .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Pfizer Service Providers

2 Service Providers

Pfizer has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P, Corporate Minority, and Acquired

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P, Corporate Minority, and Acquired

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Pfizer Team

161 Team Members

Pfizer has 161 team members, including current Chief Executive Officer, Albert Bourla.

Name

Work History

Title

Status

Albert Bourla

Chief Executive Officer

Current

Ian C. Read

Chief Executive Officer

Current

Bert Bruce

President

Current

Mikael Dolsten

Wyeth Pharmaceuticals, OrbiMed Advisors, Boehringer Ingelheim, AstraZeneca, Lund University, and Pharmacia & Upjohn

President

Current

Christy A. Fleurat

President

Current

Name

Albert Bourla

Ian C. Read

Bert Bruce

Mikael Dolsten

Christy A. Fleurat

Work History

Wyeth Pharmaceuticals, OrbiMed Advisors, Boehringer Ingelheim, AstraZeneca, Lund University, and Pharmacia & Upjohn

Title

Chief Executive Officer

Chief Executive Officer

President

President

President

Status

Current

Current

Current

Current

Current

You May Also Like

H
Hale Therapeutics

Hale Therapeutics provides Hale, a connected vaporizer pen that lowers nicotine intake over time in a bid to curb smoking addiction.

A
Atentiv

Atentiv is committed to delivering the promise of new cognitive skills for millions of children around the world so that they can achieve success in school, at home and in life. By working as a team, in partnership with educators and clinicians, the company seeks to drive transformative change in education and many other areas of unmet educational and clinical need. The ATENTIVmynd Games is a product platform of personalized digital learning tools that uses an individual's unique 'cognitive signature' of brain wave activity to measure, train and manage multiple cognitive function development that significantly improve attention and impulse control.

Limbix Logo
Limbix

Limbix makes virtual reality and digital treatment tools for therapists.

B
BRAVIS

BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

Brightline Logo
Brightline

Brightline provides pediatric behavioral health services. Brightline offers technology, data-informed progress tracking, and science-backed clinical programs together with multidisciplinary care teams that work alongside families.

Freespira Logo
Freespira

Freespira is a medical device company that is developing non-pharmaceutical treatments for individuals with panic disorders, anxiety disorders, and post-traumatic stress disorder (PTSD). The company has developed a digital therapeutic that can reduce or eliminate symptoms of panic disorder, panic attacks, and post-traumatic stress disorder by training users to normalize respiratory irregularities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.